secwatch.observer — SEC 8-K summary
======================================

Issuer:     VYCOR MEDICAL INC (VYCO)
CIK:        0001424768
Form:       8-K
Filed at:   2026-03-31T23:59:59+00:00
Accession:  0001493152-26-014079
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vycor Medical annual revenue up 17% to $1.86M; operating profit swings to positive
--------------------------------------------------------------------------------

- Total revenue $1,863,400 (+17% YoY); Vycor Medical division $1,796,070 (+18%), driven by international growth.
- GAAP operating profit of $33,900 vs loss of $9,145 in 2024; non-GAAP operating profit $145,881 (+79%).
- Gross margin 83% vs 89% in 2024 due to higher costs and international sales mix.
- NovaVision revenue $67,330 (-8% YoY); study validated NeuroEyeCoach for home use.
- Seven new peer-reviewed VBAS studies published in 2025; total clinical papers reach 50.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1424768/000149315226014079/0001493152-26-014079-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1424768/000149315226014079/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-014079

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer